Imaizumi M, Kondo T, Kamei H, Ichihashi H
Dept. of Thoracic Surgery, Nagoya University School of Medicine.
Gan To Kagaku Ryoho. 1990 Dec;17(12):2397-403.
A cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer was carried out by Kondo's group from July 1974 to December 1977. A total of 848 patients with gastric cancer underwent curative resection were eligible. Of 848 patients, 819 cases with complete description of patient's background were evaluable: Group A (surgery + MMC + 5-FU:chemotherapy) 253 cases, group B (surgery + MMC + 5-FU + OK-432 or PSK:immunochemotherapy) 282 and group C (surgery alone) 284. The 5-year corrected survival rates of total cases using Cox's proportional hazard model were 76.2% with group A, 73.6% with group B and 73.3% with group C. And the 10-year survival rates were 67.6% with group A, 64.3% with group B and 63.9% with group C. The difference in survival rate among groups A, B and C was not statistically significant. In the evaluation of prognostic factors by Cox's proportional hazard model, level of curative resection, extent of resection, histological stage and Kajitani's classification had an influence upon survival rates, in which degrees of metastasis in lymph node and serous infiltration were also involved. The significance of postoperative adjuvant immunochemotherapy has not been clarified.
近藤小组于1974年7月至1977年12月开展了一项关于手术辅助免疫化疗预防胃癌术后复发的合作研究。共有848例接受根治性切除的胃癌患者符合条件。在这848例患者中,819例有完整患者背景描述的病例可进行评估:A组(手术+丝裂霉素+氟尿嘧啶:化疗)253例,B组(手术+丝裂霉素+氟尿嘧啶+溶链菌制剂或云芝多糖:免疫化疗)282例,C组(单纯手术)284例。使用Cox比例风险模型计算的所有病例的5年校正生存率,A组为76.2%,B组为73.6%,C组为73.3%。10年生存率,A组为67.6%,B组为64.3%,C组为63.9%。A、B、C三组生存率的差异无统计学意义。在通过Cox比例风险模型评估预后因素时,根治性切除水平、切除范围、组织学分期和Kajitani分类对生存率有影响,其中还涉及淋巴结转移程度和浆膜浸润情况。术后辅助免疫化疗的意义尚未明确。